Uncovering PBA: Cathy Yaggy

**Nurse Cathy**: The most important step for me is getting a very thorough history. And that can be, first and foremost, from the chart. Looking to see if they have a neurologic injury - stroke, Parkinson’s, dementia, ALS, MS. Obviously, that has to lay the groundwork for PBA to exist.

Then I pick up the phone and talk to the family members and ask, "What was mom like before her stroke? Was she crying like this? Does she have history of mental illness?" and get more clues with that. I talk to the staff - "When are these episodes happening?" and get a little more descriptive information from them. “Does it happen in the showers? Does it happen when you’re dressing them? Does it happen at night?"

Ruling out the circumstances behind it and then asking very pointed questions of, “Does there seem to be a reason, a legitimate reason for these episodes to be happening or is it random or exaggerated? Does it make sense in the context of what’s going on around?”

**End Slate**: Avanir Pharmaceuticals, Inc.

**Onscreen Text**: Mary Catherine Yaggy, MSN, GNP-BC, is a paid consultant of Avanir Pharmaceuticals, Inc.

©2019 Avanir Pharmaceuticals, Inc. All rights reserved. AVANIR is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

MLR-NUE-US-1634-1021

**INDICATION AND USAGE**

NUEDXTA® (dextromethorphan HBr and quinidine sulfate) is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury.

**IMPORTANT SAFETY INFORMATION**

**CONTRAINDICATIONS**

**Quinidine and Related Drugs**: NUEDXTA contains quinidine, and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine.
**Hypersensitivity:** NUEDEXTA is contraindicated in patients with a history of NUEDEXTA-, quinine-, mefloquine-, or quinidine-induced thrombocytopenia, hepatitis, bone-marrow depression, lupus-like syndrome, or known hypersensitivity to dextromethorphan (eg, rash, hives).

**MAOIs:** NUEDEXTA is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), or in patients who have taken MAOIs within the preceding 14 days, due to the risk of serious and possibly fatal drug interactions, including serotonin syndrome. Allow at least 14 days after stopping NUEDEXTA before starting an MAOI.

**Cardiovascular:** NUEDEXTA is contraindicated in patients with a prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, heart failure, patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (eg, thioridazine and pimozide), patients with complete atrioventricular (AV) block without implanted pacemaker, or at high risk of complete AV block.

**WARNINGS AND PRECAUTIONS**

**Thrombocytopenia and Other Hypersensitivity Reactions:** Quinidine can cause immune-mediated thrombocytopenia that can be severe or fatal. Non-specific symptoms, such as lightheadedness, chills, fever, nausea, and vomiting, can precede or occur with thrombocytopenia. NUEDEXTA should be discontinued immediately if thrombocytopenia occurs.

**Hepatotoxicity:** Hepatitis, including granulomatous hepatitis, has been reported in patients receiving quinidine, generally during the first few weeks of therapy. Discontinue immediately if this occurs.

**Cardiac Effects:** NUEDEXTA causes dose-dependent QTc prolongation. QT prolongation can cause torsades de pointes–type ventricular tachycardia, with the risk increasing as the degree of prolongation increases. When initiating NUEDEXTA in patients at risk for QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation of QT interval should be conducted at baseline and 3 to 4 hours after the first dose. Some risk factors include use with CYP3A4 inhibitors or drugs that prolong QT interval, electrolyte abnormalities, bradycardia, or left ventricular hypertrophy or dysfunction. If patients taking NUEDEXTA experience symptoms that could indicate the occurrence of cardiac arrhythmias (eg, syncope or palpitations), NUEDEXTA should be discontinued, and the patient further evaluated.

**Concomitant Use of CYP2D6 Substrates:** NUEDEXTA inhibits CYP2D6 and may interact with other drugs metabolized by CYP2D6. Adjust dose of CYP2D6 substrates as needed.
Dizziness: NUEDEXTA may cause dizziness. Take precautions to reduce the risk of falls.

Serotonin Syndrome: Use of NUEDEXTA with selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants increases the risk of “serotonin syndrome.”

Anticholinergic Effects of Quinidine: Monitor for worsening in myasthenia gravis.

ADVERSE REACTIONS

The most common adverse reactions (incidence of ≥3% and two-fold greater than placebo) in patients taking NUEDEXTA are diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, increased gamma-glutamyltransferase, and flatulence.

These are not all the risks for use of NUEDEXTA.

Please see Full Prescribing Information at https://www.nuedextahcp.com.